Table 1.
Baseline Characteristics of the Cohorts, by Use of Anticoagulation after Index Major Hemorrhage.
| Dabigatran Cohort (N=404) |
Warfarin Cohort (N=1135) |
|||||||
|---|---|---|---|---|---|---|---|---|
| Variable | Resumed Dabigatran (n=117) |
No Oral Anticoagulation (n=217) |
Switched to Warfarin (n=70) |
P- Value |
Resumed Warfarin (n=484) |
No Oral Anticoagulation (n=626) |
Switched to Dabigatran (n=25) |
P- Value |
| Age, mean (SD) | 79.64 (8.67) | 81.9 (7.63) | 78.73 (8.34) | 0.005 | 77.95 (9.40) | 80.20 (8.96) | 76.15 (6.79) | <0.001 |
| Male sex, N (%) | 41 (35.0) | 68 (31.3) | 23 (32.9) | 0.788 | 219 (45.3) | 247 (39.5) | 13 (52.0) | 0.093 |
| Race, N (%) | 0.745 | 0.657 | ||||||
| White | 106 (90.6) | 188 (86.6) | 60 (85.7) | 400 (82.6) | 521 (83.2) | 20 (80.0) | ||
| Black | 8 (6.8) | 15 (6.9) | 5 (7.1) | 54 (11.2) | 72 (11.5) | 2 (8.0) | ||
| Hispanic | 2 (1.7) | 6 (2.8) | 3 (4.3) | 23 (4.8) | 26 (4.2) | 3 (12.0) | ||
| Other | 1 (0.9) | 8 (3.7) | 2 (2.9) | 7 (1.5) | 7 (1.1) | 0 (0.0) | ||
| Medicaid eligibility, N (%) | 43 (36.8) | 60 (27.7) | 25 (35.7) | 0.170 | 166 (34.3) | 194 (29.4) | 6 (24.0) | 0.158 |
| CHA2DS2-VASc score, mean (SD) | 5.96 (1.77) | 5.89 (1.58) | 5.77 (1.99) | 0.773 | 4.92 (1.57) | 5.08 (1.60) | 4.28 (1.56) | 0.018 |
| HAS-BLED score, mean (SD) | 4.16 (0.96) | 4.12 (0.95) | 3.94 (1.08) | 0.306 | 4.06 (0.90) | 4.12 (0.95) | 4.00 (0.76) | 0.478 |
| Use of antiplatelet agents, N (%) | 16 (13.7) | 33 (15.2) | 5 (7.1) | 0.225 | 67 (13.8) | 110 (17.6) | 5 (20.0) | 0.210 |
| No. of other CMS priority comorbidities, mean (SD)* | 7.21 (2.53) | 7.06 (2.32) | 6.53 (2.80) | 0.178 | 6.79 (2.48) | 7.00 (2.40) | 5.92 (2.60) | 0.051 |
| Type of bleeding, N (%) | <0.001 | <0.001 | ||||||
| IC | 0 (0.0) | 23 (10.6) | 5 (7.1) | 20 (4.1) | 116 (18.5) | 3 (12.0) | ||
| GI Hemorrhage | 92 (78.6) | 184 (84.8) | 53 (74.7) | 337 (69.6) | 426 (68.1) | 19 (76.0) | ||
| Genitourinary hemorrhage | 5 (4.3) | 5 (2.3) | 2 (2.86) | 42 (8.7) | 18 (2.9) | 1 (4.0) | ||
| Other | 20 (17.1) | 5 (2.3) | 10 (14.3) | 85 (17.6) | 66 (10.5) | 2 (8.0) | ||
| Length of stay,median (IQR) | 4.0 (3.0-5.0) | 4.0 (3.0-7.0) | 4.0 (2.0-7.0) | 0.768 | 4.0 (3.0-6.0) | 5.0 (3.0-8.0) | 4.0 (2.0-7.0) | 0.253 |
| Use of intensive care unit, N (%) | 39 (33.3) | 88 (40.6) | 35 (50.0) | 0.078 | 418 (30.6) | 268 (42.8) | 14 (56.0) | <0.001 |
| Trasfusion, N (%) | 39 (33.3) | 105 (48.4) | 35 (50.0) | 0.018 | 210 (43.4) | 329 (52.6) | 13 (52.0) | 0.010 |
| Surgical procedures in area affected, N (%) | 18 (15.4) | 38 (17.5) | 16 (22.9) | 0.427 | 99 (20.5) | 115 (18.4) | 6 (24.0) | 0.575 |
NOTES:
Abbreviations: CMS=Centers for Medicaid Services; IC=Intracranial; GI=Gastrointestinal; NOS=Not Otherwise Specified.
*
The list of other CMS priority comorbidities can be found in the Supplemental Methods at http://stroke.ahajournals.org.